CTX-471 attaches to the CD137 receptor’s membrane proximal epitope, leading to improved activation of T-Cells and NK Cells.
The objective of the trial is to establish IGC-AD1’s efficacy in helping dementia patients reduce neuropsychiatric symptoms.
The analytical component provides researchers with a comprehensive monitoring approach in trials.
Cut drug wastage, reduce risk, and optimise supply with advanced, integrated technologies designed to deliver increased visibility, flexibility and accuracy.
Individuals who are more prone to alcoholism are at an increased risk of breast and colorectal cancers.
Get industry leading news, data and analysis delivered to your inbox
In the study, NDI-034858 achieved statistical significance in a greater number of patients, with more reaching PASI-75.
The trial will assess ISA101b’s safety and efficacy in HPV16 positive OPC patients.
The trial launch is backed by various preclinical studies, where CMTX-101 showed anti-biofilm activity.
A monoclonal antibody, NTX1088 is directed against a transmembrane protein called PVR.
Clinical Trials Arena examines recently announced Phase III studies in the HIV therapeutic landscape.
The trial will assess IMM01-STEM’s tolerability and safety in patients with muscle atrophy.
The trial will assess the biological and clinical activity of NP137 as an add-on therapy in solid tumours patients.
The initial interim data from the trial is anticipated by the end of the first quarter of next year.
The FDA could approve the first treatment for Friedreich’s ataxia, and at least three other major trials have readouts expected by year end.
An oral TRβ agonist, ABX-002 had shown target engagement in areas of the brain linked to depression.